Luton, Bedfordshire, United Kingdom, May 30, 2025 (GLOBE NEWSWIRE) -- Global Market Outlook: Medical High-Frequency Electrotome Electrosurgical Generators Set to Surpass $2.5 Billion by 2034 Get a ...
Frequency Therapeutics’ hearing loss treatment showed early signs of efficacy last year, with some patients showing improvements after a few months. Now, as the biotech plugs away at a phase 2a study, ...
Concertgoers, rejoice: An early safety study of Frequency Therapeutics’ hearing loss drug treatment has cleared its first hurdles while showing some signs of hearing improvement in certain patients.
Frequency has brought together world-renowned scientists and researchers with extensive expertise in the fields of stem cell biology and regenerative medicine. The PCA Regenerative Medicine SAB will ...
Astellas Pharma will partner with Frequency Therapeutics to develop Frequency’s lead candidate—the Phase IIa-bound sensorineural hearing loss regenerative therapeutic FX-322—through a collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback